Clinical trials: Irritable Bowel Syndrome
Functional Gastrointestinal Disorders, Vagus Nerve Autonomic Disorder
A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders
The purpose of this study is to see if using a micro-current through a device called a TENS (Transcutaneous Electrical Nerve Stimulator) unit helps to improve functional gastrointestinal disorder (FGID) symptoms in children by…
- Conditions
- Functional Gastrointestinal Disorders, Vagus Nerve Autonomic Disorder, Irritable Bowel Syndrome, Nausea
- Trial name
- NCT04247100
- Testing
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Gisela Grotewold Chelimsky
Irritable Bowel Syndrome With Diarrhea
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
This study will evaluate the effectiveness and safety of repeat treatment with rifaximin 550 mg three times a day in patients with IBS with diarrhea who respond to initial treatment of rifaximin 550 mg three times a day.
- Trial name
- TARGET3 (NCT01543178)
- Testing
- open-label rifaximin, double-blind rifaximin
- Where
- 296 sites in United States, Germany and 1 more
- Volunteers
- 2,583 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
The Value of Bio-electrical Impedance Analysis in Irritable Bowel Syndrome
The study aim is to investigate the Bio-electrical Impedance (BIA) parameters in general, and phase angle (PhA) in particular in Irritable bowel syndrome (IBS) patients and to compare these with values from healthy controls…
- Trial name
- BIA-IBS (NCT05744258)
- Testing
- Bio-electrical impedance analysis
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Irritable Bowel Syndrome With Constipation, Functional Constipation
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation participants) of linaclotide exposure that will enroll pediatric participants…
- Trial name
- NCT04166058
- Testing
- Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 381 people
- Sponsor
- AbbVie
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 2 (NCT00724126)
- Testing
- Rifaximin
- Where
- 88 sites in United States
- Volunteers
- 637 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome
We hypothesize that duloxetine treatment will be associated with improvement in symptoms of IBS, particularly abdominal pain, in individuals without comorbid major depressive disorder.
- Trial name
- NCT00401258
- Testing
- duloxetine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mclean Hospital
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
The primary objective of this study is to assess the potential of LINZESS® (linaclotide) treatment to induce the development of anti-drug antibodies (ADAs).
- Trial name
- NCT02590432
- Testing
- Linaclotide
- Where
- 79 sites in United States
- Volunteers
- 828 people
- Sponsor
- Forest Laboratories
Irritable Bowel Syndrome
Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. There are still no effective and safe medications approved for the treatment of abdominal pain associated with bowel symptoms in IBS.
- Trial name
- NCT01786109
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Michael Camilleri
Irritable Bowel Syndrome
A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome
A study to evaluate the effectiveness of oral doses of Blautix in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT03721107
- Testing
- Blautix
- Where
- 34 sites in United States, Ireland and 1 more
- Volunteers
- 366 people
- Sponsor
- 4D pharma plc
Diarrhea-predominant Irritable Bowel Syndrome
Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg
Irritable bowel syndrome is a complex condition with a high unmet medical need for effective and safe treatment options. Lacteol® is a lactobacillus product used for adjunctive and symptomatic treatment of diarrhea.
- Trial name
- NCT01358708
- Testing
- LACTEOL® 340 mg
- Where
- 8 sites in France, Germany
- Volunteers
- 26 people
- Sponsor
- Forest Laboratories
Ulcerative Colitis, Healthy
GI Permeability Change in Response to Aquamin®
This trial is being completed to learn about how Aquamin® affects gastrointestinal permeability, or the control of material passing from inside the gastrointestinal tract through the gut wall into the rest of the body, in people…
- Conditions
- Ulcerative Colitis, Healthy, Irritable Bowel Syndrome With Diarrhea
- Trial name
- NCT04855799
- Testing
- Aquamin
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- James Varani
Irritable Bowel Syndrome Characterized by Constipation
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C.
- Trial name
- CIBS (NCT01722318)
- Testing
- Plecanatide
- Where
- 99 sites in United States
- Volunteers
- 428 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
Effects of Low FODMAP Diet on Colonic Epithelial Physiology in Diarrhea-predominant Irritable Bowel Syndrome
This research is studying whether changing an individual's diet may have an impact as a treatment or outcome for Irritable Bowel Syndrome (IBS).
- Trial name
- NCT04542018
- Testing
- a low FODMAP diet for 4 weeks
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Michigan
Ulcerative Colitis
Melatonin and Ulcerative Colitis: A Pilot Clinical Trial
Ulcerative colitis is an inflammatory bowel disease that afflicts up to one million people in the U.S. Symptoms include rectal urgency, bloody diarrhea, moderate to severe abdominal pain, fever, and fatigue.
- Trial name
- NCT00790478
- Testing
- Melatonin
- Where
- 2 sites in United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Emory University
Irritable Bowel Syndrome With Constipation
Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.
- Trial name
- NCT00380250
- Testing
- Lubiprostone
- Volunteers
- 590 people
- Sponsor
- Sucampo Pharma Americas, LLC
Irritable Bowel Syndrome
Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome
The general aim of the current study is to describe the effect of pregabalin on colonic and sensory functions in adults with constipation predominant irritable bowel syndrome (IBS-C). Study hypotheses: 1.
- Trial name
- NCT01331213
- Testing
- Pregabalin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome, Placebo Effect
Effects of Open-label vs Double-blind Treatment in IBS
The purpose of this study is to investigate placebo effects and peppermint oil in Irritable Bowel Syndrome.
- Conditions
- Irritable Bowel Syndrome, Placebo Effect, Placebos, Peppermint Oil
- Trial name
- NCT02802241
- Testing
- peppermint oil
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Beth Israel Deaconess Medical Center
Irritable Bowel Syndrome, Colitis, Ulcerative
Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders
This clinical trial hypothesize that Gut Microbiota (bacteria, viruses, fungi)play a major role in the occurrence and progression of many chronic gastrointestinal diseases like Irritable Bowel Syndrome, Inflammatory Bowel…
- Conditions
- Irritable Bowel Syndrome, Colitis, Ulcerative, Crohn Disease, Colonic Neoplasms
- Trial name
- NCT01099111
- Where
- Saudi Arabia
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- King Fahad Medical City
Irritable Bowel Syndrome With Constipation
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of Irritable Bowel syndrome with Constipation (IBS-C), in children age 7-17 years.
- Trial name
- LIN-MD-63 (NCT02559817)
- Testing
- Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C
- Where
- 48 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Forest Laboratories
Irritable Bowel Syndrome
Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
The objectives of this study are (1) to determine the efficacy of fecal microbiota transplantation (FMT), given as oral capsules, compared with placebo for the treatment of refractory diarrhea-predominant irritable bowel syndrome…
- Trial name
- NCT02328547
- Testing
- Fecal microbiota transplantation capsules
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Montefiore Medical Center